

S1 Table. Clinical data of patients included in the study.

Patient ID	Time since HIV diagnosis (months)	CD4 Cell Count (cells/ μ l)	%CD4	Viral Load (copies/ml)	Time on suppressive ART (months)	HAART regimen
1	72	800	23.12	<20	18	ABC/3TC+DTG
2	33	490	21.03	<20	28	TDF/FTC+EVG/c
3	31	560	27.92	<20	11	TDF/FTC+EVG/c
4	49	1070	38.14	<20	39	TDF/FTC/EFV
5	31	810	34.70	<20	22	ABC/3TC+DTG
6	42	1150	37.05	<20	37	ABC/3TC+RPV
7	13	1760	57.71	<20	>13	TDF/FTC+EVG/c
8	55	970	NA	<20	45	ABC/3TC+DTG
9	168	540	NA	<20	54	TDF/FTC+EVG/c
10	25	800	42.99	<20	19	TDF/FTC+EVG/c
11	35	1160	45.83	<20	31	TDF/FTC/EFV
12	276	520	29.50	<20	78	TDF/FTC+ETV
13	33	720	NA	<20	13	TDF/FTC+EVG/c
14	331	930	29.7	<20	71	TDF/FTC/EFV
15	127	960	45	<20	56	ABC/3TC+DTG
16	31	840	35.75	<20	23	TDF/FTC+EVG/c
17	18	1520	46.83	<20	6	ABC/3TC+ATV/r
18	48	850	40.64	<20	27	TDF/FTC+RPV

FTC, emtricitabine; TDF, tenofovir; 3TC, lamivudine; EFV, efavirenz; ABC, abacavir; EVG/c, elvitegravir boosted with cobicistat; DTG, dolutegravir; DRV/c, darunavir boosted with cobicistat; ETV, Etravirine; RPV, Rilpivirine; ATV/r, atazanavir boosted with ritonavir; NA, not available.